Monitor for future announcements regarding conversion of this evaluation into a commercial sale or expanded orders; follow-up deployments or contracts could signal growing market acceptance.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 18 $0.5790entry
- T+1 · 9mo ago +0.17%α +0.41% · $0.5800
- T+5 · 9mo ago +1.90%α +0.89% · $0.5900
- T+20 · 8mo ago −3.28%α +0.31% · $0.5600
- T+60 · 6mo ago −30.05%α −38.24% · $0.4050
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inspira Technologies announced the deployment of its FDA-cleared ART100 system at a top-ranked academic medical center in New York for a structured commercial evaluation. This expands its presence in the U.S. Tier-1 hospital market, supporting its commercial strategy, though no financial terms or outcomes were disclosed.
Key Facts
- Inspira Technologies deployed its ART100 system at a new U.S. academic medical center in New York.
- The institution is ranked among New York State’s top 10 hospitals in Newsweek’s World’s Best Hospitals 2025.
- The deployment is part of a structured commercial evaluation to assess clinical protocols and potential broader adoption.
- No financial figures, revenue impact, or contractual terms were disclosed.
- The ART100 is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO outside the U.S.
Financial Impact
No financial impact disclosed; no revenue, deal value, or guidance provided.
Risk Factors
- Evaluation may not lead to commercial adoption.
- No assurance of revenue generation from this deployment.
- Forward-looking statements are subject to risks and uncertainties as outlined in the company's 20-F filing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3240229 |
Track record
13 reports on IINN
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +308.27% at T+5 after the May 18, 2026 report. 3 of 3 went positive at some point.
Filters
- Oct 9, 20265w ago 6-K Neutral 4/10 No price data
- May 29, 202624w ago Press Release Mixed 5/10 Entry $3.07 to $1.87 ▼ −39.09% −38.80% vs SPY
- May 18, 202626w ago Press Release Bullish 5/10 Entry $0.3723 to $1.52 ▲ +308.27% +306.65% vs SPY
- May 11, 202627w ago Press Release Neutral 5/10 Entry $0.4070 to $0.3720 ▼ −8.60% −8.51% vs SPY
- May 1, 202628w ago Press Release Neutral 4/10 Entry $0.4680 to $0.4500 ▼ −3.85% −6.19% vs SPY
- Apr 16, 202630w ago Press Release Bullish 6/10 Entry $0.4950 to $0.5400 ▲ +9.09% +8.11% vs SPY
- Apr 14, 202630w ago Press Release Neutral 3/10 Entry $0.4750 to $0.5800 ▲ +22.11% +20.71% vs SPY
- Apr 13, 202631w ago Press Release Mixed 5/10 Entry $0.5080 to $0.5870 ▲ +15.55% +12.26% vs SPY
- Apr 6, 202632w ago Press Release Neutral 4/10 Entry $0.4110 to $0.5080 ▲ +23.60% +19.47% vs SPY
- Apr 6, 202632w ago Press Release Bullish 7/10 Entry $0.4110 to $0.5080 ▲ +23.60% +19.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers